We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Roche Acquires Signature Diagnostics to Advance Translational Research

By LabMedica International staff writers
Posted on 15 Feb 2015
Print article
Roche (Basel, Switzerland) will advance translational research for next generation sequencing (NGS) diagnostics by leveraging the unique expertise of Signature Diagnostics AG (Potsdam, Germany) in biobanks and development of novel NGS diagnostic assays.

Signature Diagnostics is a privately held translational oncology and genomics company that develops large blood plasma and tissue biobanks in multiple cancers (including colorectal and lung), constructed from multicenter prospective clinical studies. Signature uses the samples from its biobanks along with accompanying clinical progression and genetic data to develop and validate circulating cell free DNA (cfDNA) tests, toward advancing cost-effective noninvasive monitoring of patient treatment response. Signature will be integrated into Roche Sequencing Unit and will continue to focus on expanding its innovative genomic signature portfolio.

"Biobanks play an important role in uncovering the cause or origin of disease such as cancer which is important in translational research and the development of personalized therapies for patients," said Roland Diggelmann, COO, Roche Diagnostics, "Signature represents a unique bridge between high value cancer biobanks and NGS assay development. Roche plans to leverage Signature's expertise in both of these areas to accelerate the development of targeted NGS-based diagnostics in the future. Biobanks can also be used for biomarker discovery and hypothesis testing with Pharma."

"We are very pleased Roche recognizes the importance of high-quality longitudinal cancer biobanks for the development of novel NGS-based diagnostics," says Andre Rosenthal, PhD, CEO of Signature, "Joining forces with Roche is very exciting as it will allow us to further develop our NGS assays for sequencing tests using cfDNA, which may advance the development of noninvasive treatment-response monitoring for cancer patients."

Signature products are currently for research use only.

Related Links:

Roche
Signature Diagnostics


Gold Member
Troponin T QC
Troponin T Quality Control
Unit-Dose Packaging solution
HLX
New
Sulfidoleukotrienes (sLT) Assay
CAST ELISA
New
Hepato Fibrosis Assays
Hepato Fibrosis Assays

Print article

Channels

Clinical Chemistry

view channel
Image: The new saliva-based test for heart failure measures two biomarkers in about 15 minutes (Photo courtesy of Trey Pittman)

POC Saliva Testing Device Predicts Heart Failure in 15 Minutes

Heart failure is a serious condition where the heart muscle is unable to pump sufficient oxygen-rich blood throughout the body. It ranks as a major cause of death globally and is particularly fatal for... Read more

Molecular Diagnostics

view channel
Image: The bowel cancer breakthrough could result in better treatment outcomes (Photo courtesy of 123RF)

New RNA Molecules Can Help Predict Bowel Cancer Return Recurrence

Colorectal cancer accounts for 10% of all cancer-related deaths worldwide and was ranked as the second most common cause of cancer death in the United States in 2022. Currently, clinicians face diagnostic... Read more

Hematology

view channel
Image: QScout CBC will give a complete blood count in 2 minutes from fingerstick or venous blood (Photo courtesy of Ad Astra Diagnostics)

Next Gen CBC and Sepsis Diagnostic System Targets Faster, Earlier, Easier Results

Every hour is critical in protecting patients from infections, yet there are currently limited tools to assist in early diagnosis before patients reach a hospital. The complete blood count (CBC) is a common... Read more

Microbiology

view channel
Image: The InfectoSynovia test has the potential to revolutionize the diagnosis of periprosthetic joint infection (Photo courtesy of 123RF)

High-Accuracy Bedside Test to Diagnose Periprosthetic Joint Infection in Five Minutes

Periprosthetic joint infection (PJI) represents a significant global issue that is worsening as the number of joint replacements increases due to aging populations. In the United States alone, the anticipated... Read more

Pathology

view channel
Image

AI-Based Method Shows Promise for Pathological Diagnosis of Hereditary Kidney Diseases

Alport syndrome is a hereditary kidney disorder characterized by kidney dysfunction, sensorineural hearing loss, and ocular abnormalities. Early in the disease, patients experience hematuria, which is... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.